AlphaROC – AI Driven Data Science & Analytics

Body Snatchers: The Invasion of Anti-Obesity Drugs in America

As Americans debate the complex issues around weight management and body image, the landscape of anti-obesity medications is undergoing a dramatic transformation. Prescription volume for GLP-1 agonist drugs such as Ozempic and Wegovy reflect a staggering 300% surge in prescriptions from 2020 to 2022. Despite facing criticism from advocates of the body-positivity movement and those cautioning against easy fixes to obesity, the demand for these medications has in particular significantly boosted market leader Novo Nordisk – so much so that the company has single-handedly begun to impact Denmark’s national economic statistics.  The surge has also triggered a wave of new, potentially more effective treatments like Eli Lilly’s tirzepatide-based Mounjaro and Zepbound. Below, we delve into this remarkable trend, shedding light on the expanding public consciousness, the subtle demographic patterns around consumption, and the waning apprehensions concerning potential side effects.